Albumin Replacement in Hepatic Hydrothorax
For therapeutic thoracentesis in hepatic hydrothorax, administer 20-25% intravenous albumin at 6-8 g per liter of pleural fluid removed when the volume exceeds 5 L, and consider albumin for smaller volumes if the patient has hypotension, renal insufficiency, or electrolyte abnormalities.
Evidence-Based Dosing Algorithm
The most recent 2025 AGA guidelines provide the clearest framework 1:
- Volume >5 L removed: Give 6-8 g albumin per liter of fluid drained (strong recommendation)
- Volume <5 L removed: Consider albumin if patient has:
- Hypotension
- Renal insufficiency
- Electrolyte abnormalities
This mirrors the well-established approach for large-volume paracentesis, which has high-quality evidence 2. The 2021 Gut guidelines specifically state albumin after paracentesis >5 L carries high quality evidence with a strong recommendation 2.
Practical Application to Thoracentesis
While the guidelines primarily address paracentesis, the 2025 AGA update explicitly extends these principles to hepatic hydrothorax management 1. The pathophysiology is identical—both procedures remove protein-rich fluid and risk post-procedural circulatory dysfunction (PPCD), which albumin prevents by maintaining oncotic pressure and effective arterial blood volume.
Key dosing details:
- Use 20% or 25% albumin solution (not 5%)
- Administer after the procedure is completed
- Calculate total dose: (Liters removed) × (6-8 g)
- Example: 6 L removed = 36-48 g albumin total
When to Use Lower Thresholds
The Korean KASL guidelines 3 and FDA labeling 4 support albumin use even with smaller volumes in high-risk patients. Consider albumin for <5 L removal if:
- Hemodynamic instability: Baseline hypotension or tachycardia
- Renal dysfunction: Creatinine >1.2 mg/dL or rising trend
- Severe hypoalbuminemia: Serum albumin <2.5 g/dL
- Acute-on-chronic liver failure (ACLF): Any grade
- Severe hyponatremia: Sodium <130 mmol/L
Common Pitfalls to Avoid
Don't skip albumin based on volume alone. The 5 L threshold is a guideline, not an absolute rule. A frail patient with baseline renal dysfunction removing 4 L may benefit more from albumin than a robust patient removing 6 L.
Don't use crystalloids as a substitute. Normal saline does not prevent PPCD as effectively as albumin in cirrhotic patients 5. The FDA label explicitly states albumin may be required after ascitic fluid removal to support blood volume 4.
Don't delay administration. Give albumin immediately after completing the thoracentesis, not hours later. The goal is to prevent circulatory dysfunction, not treat it after it develops.
Emerging Evidence on Dose Reduction
Recent 2026 data suggests lower doses (2-6 g/L) may be non-inferior to standard dosing for preventing PPCD and renal dysfunction 6. However, this evidence comes from small studies with methodological limitations. Until larger trials confirm safety, stick with the established 6-8 g/L dosing to prioritize patient safety and avoid acute kidney injury, which significantly worsens mortality.
Alternative Considerations
The 2024 AGA vasoconstrictor update 5 examined whether vasoconstrictors (terlipressin, midodrine) could replace albumin after large-volume paracentesis. While some small studies showed equivalence, evidence remains insufficient to recommend this approach, and one study showed increased AKI with vasoconstrictors. One case report described successful terlipressin use for refractory hepatic hydrothorax 7, but this is anecdotal and not guideline-supported.
Definitive Management Context
Remember that albumin replacement is symptomatic treatment only. The 2021 Gut guidelines emphasize that TIPS should be considered for refractory hepatic hydrothorax 2, and the 2018 EASL guidelines recommend TIPS as definitive treatment or bridge to transplantation 8. Liver transplantation remains the only curative option 8, 9.